Research programme: glycolipid replacement therapies - Seneb BioSciences
Alternative Names: SNB 2401; SNB-4050Latest Information Update: 28 Aug 2020
At a glance
- Originator Seneb BioSciences
- Class Antihypoglycaemics; Antiparkinsonians; Glycolipids
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Huntington's disease; Hyperinsulinaemia; Neuronal ceroid lipofuscinosis; Parkinson's disease
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Hyperinsulinaemia in USA
- 28 Aug 2020 No recent reports of development identified for research development in Huntington's-disease in USA
- 28 Aug 2020 No recent reports of development identified for research development in Neuronal ceroid lipofuscinosis in USA